// App-Quantinova.ai

39 : Phase I/II Trial of Lenalidomide and High-Dose Melphalan As Preparative Regimen for Relapsed Myeloma

Researchers

Presenter

  • Muzaffar H. Qazilbash

Principal Investigators

  • Peter Thall

  • Patricia S Fox

  • Chitra Hosing

  • Pei Lin

  • Elizabeth J. Shpall

  • Robert Z. Orlowski

  • Richard E. Champlin

  • Nina Shah

  • Qaiser Bashir

  • Jatin Shah

  • Simrit Parmar

  • Partow Kebriaei

  • Yago L. Nieto

  • Yvonne Dinh

  • Uday R. Popat

Medical Centers

  • Dept of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX

  • Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX

  • Lymphoma, MD anderson Cancer Center, Houston, TX

  • Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX

  • Pediatrics, UTMD Anderson Cancer Center, Houston, TX

  • Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Deep vein thrombosis

  • Arrhythmia

  • Pulmonary embolism

  • Venous thrombosis

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Melphalan

Outcome

  • N/A

Study Design

  • adaptive

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved